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Abstract
Background: Mammary tumors are among the most frequent neoplasms in female dogs, but the strategies
employed in animal treatment are limited. In human medicine, hormone manipulation is used in cancer therapy.
Tamoxifen citrate is a selective inhibitor of oestrogen receptors and exerts a potent anti-oestrogen effect on the
mammary gland. The aim of this study was to evaluate the adverse effects when exposing healthy female dogs to
tamoxifen.
Methods: Tamoxifen was administered for 120 days at a dose of 0.5 or 0.8 mg/kg/day to either intact or spayed
female dogs. The effects were assessed through clinical examination, haematology, serum biochemistry,
ophthalmology and bone marrow aspirate examination. Ovariohysterectomy was performed and the uterus
examined by histopathology.
Results: Vulva oedema and purulent vaginal discharge developed with 10 days of tamoxifen exposure in all groups.
Pyometra was diagnosed after around 90 days of exposure in intact females with frequencies increasing during the
following 30 days of exposure. Up to 50% of dogs within the groups developed retinitis but none of the dogs had
signs of reduced visual acuity. The prevalence of retinitis in each group was similar after 120 days of exposure.
Haematological, biochemical and bone marrow changes were not observed. Due to the high risk of developing
pyometra after prolonged exposure to tamoxifen, only spayed animals should be given this medication.
Conclusions: A dose of 0.8 mg tamoxifen/kg body weight/day is recommended when treating tamoxifen-
responsive canine mammary tumors. Due to the high risk of developing pyometra, ovariohysterectomy is
recommended.
Background
The frequency of cancer and other diseases related to
aging in pet animals has increased in recent years due
to increased life expectancy [1].
Mammary tumors are among the most frequent neo-
plasms in female dogs [1-5]. Despite their importance
and high incidence, tumoral extirpation is often the pre-
ferred therapy. However, approximately 48% of dogs
with mammary carcinoma die or are euthanized within
one year after surgical removal of the primary tumor or
recognition of metastases [6]. Thus, it is necessary to
adopt low-cost alternative therapeutic approaches that
can increase overall survival and welfare.
In human medicine, systemic therapies such as che-
motherapy and hormone manipulation are used in cancer
therapy. Tamoxifen citrate is a selective inhibitor of oes-
trogen receptors and exerts a potent anti-oestrogen effect
on the mammary gland [7,8]. Previous studies have eval-
uated the efficacy of tamoxifen in preventing the recur-
rence of canine mammary tumors [9]. In that study,
tamoxifen was administered orally at a mean dose of
around 1 mg/kg body weight (BW). However, 56% of the
animals developed complications such as pyometra, vul-
var swelling and pseudogestational behaviour thus show-
ing a need to assess drug tolerance in female dogs [9].
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to minimize adverse effects [10].
Considering the lack of non-surgical therapeutic
resources for canine mammary neoplasms and the pro-
ven benefits of tamoxifen in treating human breast
tumors, studies of the value of tamoxifen medication in
canine medicine is needed. The epidemiological [11],
clinical [4,12,13], biological [4,14], and genetic similari-
ties [15] between human breast cancer and canine mam-
mary tumors allow comparisons to be made [5].
The aim of this study was to evaluate adverse effects
of tamoxifen exposure to healthy female dogs.
Methods
Animals
This study was approved by the Brazilian Committee of
Ethics in Animal Experimentation, CETEA/UFMG (Pro-
tocol number 40/2006). The dogs were forwarded for
adoption after completion of the study.
Healthy female mixed breed dogs aged 4 years ± 2.3
years, with a mean BW of 20 kg were used. Initially, the
dogs were subjected to a clinical examination including
haematology, biochemistry, ophthalmology, and bone
marrow aspirate examination as described below. Dogs
were only included if healthy. However, ophthalmologic
changes were accepted, but dogs having eye lesions were
excluded from the ophthalmology study parts.
The animals were randomly distributed into four
groups:
A: 5 intact animals receiving 0.5 mg tamoxifen citrate/
kg BW/day;
B: 5 spayed animals receiving 0.5 mg tamoxifen
citrate/kg BW/day;
C: 5 intact animals receiving 0.8 mg tamoxifen citrate/
kg BW/day;
D: 5 spayed animals receiving 0.8 mg tamoxifen
citrate/kg BW/day.
Ovariohysterectomy was performed in dogs assigned
to groups B and D approximately 90 days before enter-
ing the trial. The surgical procedure, anaesthetic proto-
col and immediate post-operative care were similar for
all dogs. The animals were kept in experimental kennels
from UFMG/Brazil with free access to food and water.
Drug exposure
Tamoxifen citrate (Taxofen® , Blaüsiegel, Cotia/Brazil)
was administered once a day for 120 days at the same
time during feeding at a dose of either 0.5 mg or 0.8 mg
per kg BW. The BW was determined monthly and the
total dose adjusted to the precise BW.
Examinations
Examinations were conducted with intervals of 10 days
starting with a pre-exposure examination (T00) followed
by examination after 10 days of tamoxifen exposure
(T01) and so on until 120 days of exposure (T02 to
T12). The dogs were not euthanized at the end of the
study, but ovariohysterectomy was performed at T12 for
intact females (groups A and C) and the uterus sub-
jected to pathological examination.
Clinical examination, haematology and serum bio-
chemistry was performed at T00 to T12.
Clinical examination included evaluation of general sta-
tus, measurement of rectal temperature, heart rate, and
respiratory rate, inspection of mucosal membranes and
skin, inspection and palpation of lymph nodes, joints,
external genitalia, and mammary glands, and palpation of
the abdominal cavity with contents. Abdominal ultraso-
nography was applied if pyometra was suspected.
Haematology was based on ethylenediaminetetraacetic
acid (EDTA) stabilized blood samples taken from the
cephalic vein. Serum biochemical analyses were done for
alanine transaminase (ALT), aspartate transaminase
(AST), gamma glutamyl transpeptidase (GGT), alkaline
phosphatase (ALP), bilirubin (direct (DB), indirect (IB)
and total (TB)), urea, creatinine, calcium and cholesterol.
Ophthalmological examinations were performed by a
specialist at T00, T06 and T12. Two drops of mydria-
tic eye solution (Mydriacyl®, Tropicamide, 1%) were
applied to each eye 15 min before examination of the
fundus. Examinations were conducted with a HEIN-
EEN 30 Indirect Ophthalmoscope and BETA 200
Direct Ophthalmoscope.
Bone marrow aspirate examinations were performed at
T00, T06 and T12. The breastbone region was trimmed
and disinfected with 70% ethanol. Lidocaine (2%) was
used for local analgesic. Bone marrow was aspirated
through a 40 × 12 hypodermic needle and a disposable
10 mL syringe. The slides were air-dried and subjected
to May-Grünewald Giemsa staining before microscopy.
Samples for histopathology were fixed in 10% neutral
buffered formalin, processed by routine methods for his-
tology and embedded in paraffin. Histological sections
of 4 μm were haematoxylin and eosin stained. Uterine
lesions were classified as described by Dow [16].
Statistical analysis
To evaluate the parametric data from the haemograms,
biochemistry and bone marrow aspirate examination,
ANOVA with a SNK test was performed. The Kruskal-
Wallis test [17] was used to evaluate non-parametric
haemograms, biochemical data and bone marrow aspi-
rate results.
Results
Clinical findings
All dogs were found healthy before entering the trial.
Vulva oedema and purulent vaginal discharge (Figure 1)
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groups (Table 1). Pyometra (Figure 1) was diagnosed
after around 90 days of exposure in intact females with
frequencies increasing during the following 30 days. Two
dogs developed pyometra in group A, while 4 dogs devel-
oped pyometra in group C. Rare events of vomiting, diar-
rhoea and appetite loss were observed throughout the
period of the experiment. Dogs developing pyometra
were submitted to ovariohysterectomy and excluded
from the study (Table 1). Vaginal cytology was performed
to evaluate oestrus cycles, but was inconclusive.
Pathology
Two animals in group A developed cystic endometrial
h y p e r p l a s i at y p eIw i t hp r o liferation of endometrial
glands, cyst formation and endometrial polyps with no
inflammatory reaction (Figure 2). The predominant
pathologic findings in cases of pyometra were symmetri-
cal distension of the uterine horns with dark-stained
serosal surface and congestion. The uterine content was
purulent or opaque red-brown in color. The mucosa
had uneventhickness with irregular superficial haemor-
rhages, and in other portions obviously hyperplasia,
sometimes with small cysts. Microscopically, the most
significant feature was the endometrial hyperplasia asso-
ciated with haemorrhage and presence of polymorpho-
nuclear cells in the glandular lumen. The other three
animals in group A presented cystic endometrial hyper-
plasia type III, with mononuclear and polymorphonuc-
lear infiltration in the periglandular endometrial stroma
associated with haemorrhage. Two animals in group A
also presented squamous metaplasia of the endometrial
epithelium (Figure 2). Only one animal in group C pre-
sented cystic endometrial hyperplasia type I, while three
Figure 1 Animal: C3, Pyometra. (A) Intact female dog with purulent vaginal discharge after oral administration of tamoxifen, 0.8 mg/kg/day, for
100 days. (B) Ultrasonography revealing uterine body (1.5 cm) and uterine horns slightly dilated, thickened uterine wall with irregular mucosa
and retention of secretion within the organ. (C) Uterine histopathology after ovariohysterectomy revealing cystic endometrial hyperplasia type III
associated with hemorrhage. HE, Obj. 4×. (D) Detail showing presence of polymorphonuclear cells in glandular lumen. HE, Obj. 60×.
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type II associated with mononuclear cells (macrophages,
lymphocytes and plasmacells) with superficial subepithe-
lial haemorrhage. One animal also developed squamous
metaplasia and endometrial polyps. One animal pre-
sented cystic endometrial hyperplasia type III (Figure 1).
Ophthalmology
Three animals (A4, B3 and C5) that had ophthalmologi-
cal alterations at T00 were excluded. Up to 50% of dogs
within the groups developed retinitis during the study
(Table 1). Once a dog had developed retinitis, this condi-
tion remained throughout the study. Retinitis was charac-
terised by the presence of black dots on tapetal area [18].
None of the dogs had signs of reduced visual acuity. The
prevalence of retinitis at T12 in the exposure groups (A
+B: 0.5 mg and C+D: 0.8 mg) was non-significant.
Haematology and biochemistry
Evaluation of haematological and biochemical profiles
were restricted to the period T00 to T08 as several dogs
were removed from the study during the last time of the
trial (Table 1). The mean values for erythrocytes, hae-
moglobin, globular volume, platelets, ALT, AST, GGT,
ALP, IB and calcium remained within the normal ranges
for all dogs [19].
Slight increases were observed in the mean values of
total leukocytes at T01, T02 and T07 in group B and
T02 in group D (data not shown).
Bone marrow aspirate examination
The mean values of cellularity, megakaryocytes, metaru-
bricytes, lymphocytes, plasmacells and monocytes
remained within the normal range [20] for all dogs
throughout the trial.
Discussion
Oedema of the external genitalia as seen in dogs of all
groups develops due to the agonist action of tamoxifen
on genital hormonal receptors. After ovariohysterect-
omy, the uterine stump may develop pyometra. This
was not observed in the present study (groups B and D)
although ultrasonography was applied to all animals
having vaginal discharge. The cause of vaginal discharge
in these animals remained unsolved.
The agonist action of tamoxifen on the human uterus
promotes adverse effects such as endometritis and endo-
metrial hyperplasia. These are considered pre-malignant
lesions thus increasing the risk for development of
endometrial carcinoma [21-24]. It is evident that, as in
women, intact female dogs exposed to tamoxifen
develop endometrial cell proliferation most likely due to
the agonist stimulation of uterine oestrogen receptors.
The results corroborate previous studies [9,10] suggest-
ing that tamoxifen causes oestrogenic stimulation of
canine endometrial cells even in low doses. The number
of oestrogen receptors increases due to hormonal stimu-
lation with consequent endometrial hyperplasia and an
increased number of progesterone receptors [9]. The
serum level of this hormone remains unaltered, but as
the number of receptors is increased, leukocyte recruit-
ment to the uterus is reduced and uterine shrinkage is
impaired. This process promotes reduction of uterine
immune defences and facilitates ascending bacterial
infections, mainly caused by Escherichia coli, unleashing
pyometra [25].
Table 1 Summary of genital tract symptoms and eye lesions.
Days of tamoxyfen treatment
Group Symptom 0 10 20 30 40 50 60 70 80 90 100 110 120
A Oedema 0 5 5 5 555555 5 3 *3 *
Discharge 0 3 2 1 215535 5 3 *3 *
Retinitis 1 - - - - - 1 - - - - - 3
B Oedema 0 5 5 5 555555 5 5 5
Discharge 0 3 1 1 1155 2 5 5 5 5
Retinitis 1 - - - - - 2 - - - - - 2
C Oedema 0 5 5 5 555553 *3 *1
# 1
#
Discharge 0 2 1 5 235113 *3 *1
# 1
#
Retinitis 1 - - - - - 1 - - - - - 1
D Oedema 0 5 5 5 555555 5 5 5
Discharge 0 0 2 1 131321 3 2 2
Retinitis 0 - - - - - 0 - - - - - 2
* group size = 3,
# group size = 1, - eyes not examined
Number of dogs having vulva oedema, purulent vaginal discharge and retinitis following oral exposure to tamoxifen at daily doses of either 0.5 mg/kg body
weight (groups A and B) or 0.8 mg/kg body weight (groups C and D). Dogs in groups B and D were spayed before the study. Each group consisted initially of 5
dogs, but animals developing pyometra or had eye lesions before tamoxifen exposure were removed from the study thus reducing the group size.
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mous metaplasia of the endometrial epithelium, prob-
ably due to estrogenic stimulation as seen in women
treated with tamoxifen [26,27] and dogs with sponta-
neous cystic endometrial hyperplasia complex-pyometra
[28]. Endometrial polyps were found in one case. This
type of lesion has also been reported in women after
treatment with tamoxifen [21,22,26].
The ophthalmological alterations are similar to those
found in women treated with tamoxifen at 20 mg dose
per kg BW for 5 years. However, the prevalence seems
to be higher in dogs even though they were exposed to
a lower dose and for a shorter period. This discrepancy
m a yb er e l a t e dt oad i f f e r e n c ei ns p e c i e ss e n s i b i l i t y ,
since the mechanisms of action of tamoxifen are related
to specific variant oestrogen receptor expression in dif-
ferent cell types and different mechanisms of DNA-
receptor interaction. Thus, tamoxifen acts more as
agonist than antagonist in canines thus suggesting spe-
cies differences [29]. The lower dose groups (A and B)
presented ophthalmological lesions after 60 days of
exposure suggesting variation in sensibility not related
to dose or hormone levels (intact or spayed animal). In
human medicine, eye lesions are reversible after suspen-
sion or termination of treatment [30-33]. It is therefore
expected that such lesions will also be reversible in
canine species after treatment is suspended.
On the basis of previous studies [9,10], doses of 0.5
a n d0 . 8m g / k gB W / d a yw e r ec h o s e n .C o n s i d e r i n gt h e
risk of developing pyometra when administering tamoxi-
fen to intact female dogs, it is suggested that this medi-
cation be prescribed to spayed animals only. Since there
was no difference between the lower and higher dose
groups in the other side-effects induced by tamoxifen,
the higher dose may increase the chances of therapeutic
success.
Figure 2 (A and B): Animal: A2 (intact, 0.5 mg/kg/day). (A) Cystic endometrial hyperplasia type I. Endometrial proliferation not associated
with stromal inflammatory infiltration. HE, Obj. 20×. (B) Endometrial polyp formation. HE, Obj. 4×. (C and D): Animal: A4 (intact, 0.5 mg/kg/day).
(C) Cystic endometrial hyperplasia type III with squamous metaplasia of endometrial cover epithelium and hemorrhage. HE, Obj. 20×. (D) Detail
showing squamous metaplasia of endometrial cover epithelium and haemorrhage. HE, Obj. 60×.
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Tamoxifen may become an important compound in
veterinary medicine considering its therapeutic potential
for increasing the overall survival rate of female dogs
with mammary tumors, if its side effects are correctly
assessed and controlled. A dose of 0.8 mg tamoxifen/kg
BW/day for at least 120 days is recommended.
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